Home » Posts tagged 'mxo'

Tag Archives: mxo

Andrew Hore Quoted Micro 22 April 2019

NEX EXCHANGE

IMC Exploration Group (IMCP) has published the prospectus for its move to a standard listing. No fundraising is planned to accompany the flotation. Management believes that IMC has enough working capital for 12 months. There was €152,878 in cash available at the end of January 2019. This takes account of the statutory spending on its licences.

Block Commodities (BLCC) is calling a general meeting to enable shareholders to decide whether the company should become involved in the medicinal cannabis sector.

Ananda Developments (ANA) owns 15% of LHT, the owner of hapac medicinal cannabis inhaling technology. The hapac products are being sold in Italy and the product range is being widened. Other investments are being assessed.

Ace Liberty and Stone (ALSP) has declared a second interim dividend of 0.83p a share.

Anne Yerburgh has been replaced as chairman of Daniel Thwaites (THW) by chief executive Richard Bailey, although she remains as a non-executive director in order to represent family shareholders. A replacement is being sought for former non-executive director Nick Mackenzie.

Queros Capital Partners (BFD) has raised £305,000 from the issue of 8% unsecured bonds 2025. This will be used to provide bridging finance to UK businesses.

Chris Akers has a 3.97% stake in High Growth Capital (HASH) following the purchase of the intellectual property of Malta-based BDD, a company he founded. RRNB Capital Ltd has increased its shareholding from 1.92% to 9.95%, while Fujairah has raised its stake from 2.31% to 8.59%. High Growth Capital has completed the acquisition of additional shares in AI company Sentiance to take its stake to 15%. Whitman Howard has been appointed as corporate adviser and broker.

AIM  

Modern Water (MWG) reported its 2018 results at 6.19pm o the Thursday before Good Friday. Revenues increased by 18% to £4.2m and the reported loss was more than halved from £5.23m, although this included a £1.53m goodwill write off, to £2.47m. This appears to be the first time that Modern Water has slipped out results after the market has closed for the week. Let us hope that this does not become a habit. Serial offender Immunodiagnostic Systems Holdings (IDH) managed to put out its statement a bit earlier but after the close of the market. More can be found at https://ukinvestormagazine.co.uk/why-you-should-avoid-immunodiagnostic-systems-holdings/.

Enterprise software provider Sanderson (SND) says interim trading was ahead of expectations and further progress is expected in the second half. Interim revenues improved from £14.6m to £17m and underlying operating profit is one-third higher at £2.8m, which is partly due to accounting changes. Like-for-like operating profit would be one-fifth higher. Net cash was £3.29m at the end of March 2019. The order book is worth £8m. The interims will be published on 15 May.

Sheikh Ahmed Bin Dalmook Al Maktoum is investing £534,000 in MX Oil (MXO) for a 29.86% stake. He will appoint a non-executive chairman. This is part of a placing raising £680,000 at 0.04p a share. There are also 800 million warrants being issued that are exercisable at 0.04p over a five year period. Options over 10% of the enlarged share capital will be issued to management. The Aje field, where MX has a 5% investment is producing at around 3,150 barrels of oil per day and cash generated is being used to reduce project debt. The Aje field should start generating free cash in 2020 and that could move MX into profit in the first half of 2020. MX plans to consolidate 100 existing shares into one new share and change its name to ADM Energy.

Chief executive Sean Smith has bought 126,624 shares in biopesticide products developer Eden Research (EDEN) for 10.25p each. Finance director Alex Abrey has acquired 50,000 shares at 10.1p each. House broker Shore forecasts an increase in revenues from £2.8m to £3.7m in 2019, although the loss is expected to rise to £900,000. Shore expects Eden to move into profit in 2021.

PowerHouse Energy (PHE) has gained its first revenue generating contract for its DMG technology in conjunction with partner Waste2Tricity. Revenues will come from IP, design rights and licensing, followed by operational engineering.

Parity (PTY) is increasing its focus on the data analytics market and has appointed a new boss of consultancy services. Pre-tax profit halved to £850,000 in 2018 and a further decline is expected in 2019. Net debt is expected to remain at around £1m. Revenues are expected to continue to decline but there should be a greater proportion of the business coming from higher margin activities and profit is expected to bounce back to £1.5m in 2020.

Fryer and grease management services provider Filta (FLTA) increased revenues by 23% to £14.2m in 2018, while underlying pre-tax profit improved from £1.81m to £2.2m. This is before any significant contribution from the Watbio acquisition, which cost savings appear to be on course. A 2019 pre-tax profit of £3.8m is forecast.

Nektan (NKTN) is selling a 57.5% stake in Respin for £300,000 to a new purchaser because the previous deal could not be completed at a higher price due to the fact that buyer could not raise the finance. The online gaming firm says that it owes £3.6m in tax to the HMRC and it is likely to need additional cash to pay the bill.

TruFin (TRU) plans to sell its stake in unsecured consumer finance provider Zopa for £44.5m, an increase of 22% on the 2017 valuation, and investing £25m in manufacturing finance provider Distribution Finance Capital, which will be floated on AIM in early May. There should also be £10m returned to investors later this year. That will leave early payment services provider Oxygen Finance and Satago Financial Solutions, which provides working capital to small businesses.

Delayed results from consumer care products supplier Venture Life Group (VLG) show revenues 17% ahead at £18.8m and nearly all the growth came from the company’s brands. Pre-tax profit improved from £63,000 to £710,000. Net cash was £5.8m so the company has funds to make additional acquisitions.

Yourgene Health (YGEN) has raised £11.8m at 10.25p a share and that will be used to fund the £6.3m cash payment for molecular diagnostics developer Elucigene, which will cost £9.2m in cash and shares.

Managed services provider Redcentric (RCN) says net debt was £17.6m at the end of March 2019, compared with estimates of £20.2m. Pre-tax profit is expected to rise from £8m to £8.7m.

D4T4 Solutions (D4T4) has announced that its 2018-19 results will be ahead of expectations. This led to a pre-tax profit upgrade from £5.7m to £5.8m, but earnings per share were upgraded from 12.1p to 13.3p due to a low tax rate.

Evgen Pharma (EVG) has raised £5m through a placing at 13p a share. The cash will boost the balance sheet while management undertakes partnership discussions and additional work on SFX-01. The phase IIb data for SFX-01 in subarachnoid haemorrhage is expected in the third quarter of 2019.

Directa Plus (DCTA) doubled its total income to €2.5m in 2018. The graphene-based products developer has net cash of €5.2m, following a €3m outflow from operations.

Ariana Resources (AAU) says that the Kiziltepe gold mine produced 7,296 ounces of gold in the first quarter of 2019. That was lower than the fourth quarter of 2018, but it is ahead of the average annualised quarterly guidance.

IG Design (IGR) is set for 10% organic sales growth in the year to March 2019 and total revenues rising from £327.5m to £447m. Pre-tax profit is expected to grow from £21.4m to £29.5m. There could be further merger benefits to come from the Impact Innovations acquisition.

Europa Oil and Gas (EOG) is selling its 20% stake in PEDL143 in the Weald Basin to UK Oil and Gas (UKOG) for £300,000.

MAIN MARKET 

Plastics and panels supplier Tex Holdings (TXH) made a small loss in 2018 following accounting changes to the recognition of revenues and there is no final dividend. Trading levels were lower in the second half. Tex is in breach of some of its bank loan covenants. The major shareholder continues to support the group. The share price fell by more than one-quarter.

Electronic products distributor DiscoverIE (DSCV) is on course to improve its full year pre-tax profit from £21.8m to £27.7m. The group has raised £29m at 400p a share in order to finance the acquisitions of US-based transformers and magnetic components manufacturer Hobart Electronics and UK-based rugged and submersible sensors manufacturer Positek. The total initial consideration is £15.9m.

Fasteners supplier Trifast (TRI) says full year profit is slightly better than expected even though demand from China has been reduced due to tariff wars with the US. Net debt was £15m at the end of March 2019 and it has agreed a new four-year bank facility of £80m. This could be used for acquisitions.

Argo Blockchain (ARB) has set the date for its requisitioned general meeting, which will be held on 16 May. The requisition came from an entity owning 13.8% that is controlled by Frank Timis, who does not believe that the company will provide a satisfactory return to shareholders with its current cryptomining strategy. The plan is to remove Jonathan Bixby and Mike Edwards as directors and appoint another director. Argo has more cash than its market capitalisation. Cash operating costs have been reduced to £280,000, compared with £500,000 of potential revenues expected in May.

Kazakhstan-focused vanadium miner Ferro-Alloy Resources (FAR) is already spending the money it raised when it gained a standard listing last month. Equipment, a mobile crane and vehicles have been acquired. The design of the extension to the existing facilities and for the connection to the high voltage power line has been completed. The share price has almost halved from the placing price of 70p to 37.37p. More background information can be found at https://ukinvestormagazine.co.uk/ferro-alloy-resources-goes-to-discount-on-first-day/.

BATM (BVC) has won an initial $2m armed forces contract for cyber security and this lasts 18 months.

Emmerson (EML) has signed heads of agreement for an offtake agreement for 100% of the production from the Khemisset potash project.

Andrew Hore

Quoted Micro 18 September 2017

NEX EXCHANGE

Good Energy (GOOD) is hoping that efficiency improvements will help it to grow its profit. So far annualised savings of £1m have been made with more to come in 2018. Customer churn meant that electricity and gas customers were 1% lower in the first half. In the six months to June 2017, revenues were 16% higher at £52m but pre-tax profit was 37% lower at £700,000 due to restructuring and investment costs. Net debt was £60.4m.

Blockchain-focused investment company Kryptonite1 (KR1) has sold tokens relating to Golem, Melonport and Omisego for significant multiples of their buying prices. The gain on the disposals was nearly £400,000 with the majority coming from the Omisego disposal. The holding in Bancor has been sold for the original acquisition price. Kryptonite1 has invested £100,000 in the FOAM project seed funding round and it will receive discounted tokens in the public token offer in the fourth quarter. A further £100,000 has been invested in 208,333 tokens in the pre-sale of the Enigma Catalyst project. There has been £202,000 invested in the private sale of tokens in the RChain project and £120,000 in Rocketpool tokens. Keld Hans van Schreven has been appointed an executive director of Kryptonite1.

Block Energy (BLOK) is raising $600,000 from the sale of its Ghanaian mining assets. An initial $50,000 has been received and $550,000 will be paid by the end of 2017. The cash will be reinvested in the company’s oil and gas assets in Georgia.

Karoo Energy (KEP) is making progress towards an AIM quotation. Andrew Smith, who has worked in the finance functions of a number of AIM companies, has been appointed as a non-executive director.

WMC Retail Partners (WELL) has asked for trading in its shares to be suspended while it clarifies its financial position.

AfriAg Global (AFRI) has raised £200,000 at 0.25p a share. Via Developments (VIA1) has issued a further £300,000 of 7% debenture stock 2020. That takes the debenture stock in issue to £4.9m.

EPE Special Opportunities (ESO) had a NAV of 412.26p a share at the end of July 2017. The flotation of Luceco has helped to boost NAV.

AIM

Pennant International (PEN), which provides training and simulation equipment and services for aircraft and defence equipment. The interim profit was £1.1m, compared with around breakeven in the first half of 2016. An electro-mechanical trainer and courseware contract with a MoD contractor has been changed so second half revenues will be lower than expected but Pennant still has the contract and the changes mean it will probably earn more over the medium-term. This year’s profit will be flat at around £2.1m because of the lack of contribution from the contract. The order book of £42m includes £15m to be delivered in 2018, compared with forecast revenues of £18.5m.

Audio visual products distributor Midwich Group (MIDW) reported a one-third increase in interim revenues to £212m. Organic growth was 15%. Margins have fallen but they remain relatively strong. The van Domburg acquisition takes the group into the Benelux countries. Midwich is on course to increase full year pre-tax profit from £17.9m to £22.1m. Midwich will join the FTSE AIM 50 index later in September.

Group Eleven, which is on course for a flotation in Toronto, has acquired Teck’s 76.56% stake in the Stonepark zinc licences in Limerick, Ireland, where Connemara Mining (CON) owns the remaining 23.44%. Connemara took the decision to hang on to its stake even though it could have received C$2.8m and a 1% net smelter royalty. Stonepark is west of the Pallas Green zinc deposit.

Wynnstay Group (WYN) says it is placing its pet retail business Just for Pets into administration. In the six months to April 2017, the business lost £250,000 on revenues of £7m. Wynnstay made an operating profit of £4.24m in the same period. The Just for Pets business has net assets of £2.2m and there is likely to be a significant write-off.

MX Oil (MXO) is seeking to broaden its investing policy so that it is not purely focused on natural resources and also covers oil services and energy activities, where opportunities are lower risk. MX has warned that the carrying value of its investment in Nigerian oil assets may have to be revised.

Central Rand Gold Ltd (CRND) is seeking additional finance and this is likely to be highly dilutive for existing shareholders. The disposal of some or all of the company’s interests is also a possibility.

CSF Group (CSFG) has accepted a conditional indicative offer for one of its subsidiaries for a nominal amount. That would significantly improve the financial position of the group due to a reduction in liabilities. Net liabilities were RM27.5m at the end of September 2016. Last October, shareholders voted against cancelling the AIM quotation.

Kin Group (KIN) hopes to resurface after a company voluntary arrangement and a share placing. The administrator has sold the main assets of the core business have been sold to Australia-based SMG Investment Holdings for £50,000. The shares remain suspended.

Investment company Adams (ADA) has bought shares in fully listed-Petrofac (PFC), which is the subject of a Serious Fraud Office investigation. Adams has invested £941,000 at an average share price of 447.66p a share in the oil services provider. Adams has £100,000 left in the bank.

MAIN MARKET

Standard list shell Silver Falcon (SILF) is buying a US biotech focused on blood diseases such as bone marrow failure and leukaemia. The main product of Hemogenyx is still at preclinical stage but preparing to move into clinical trials over the next 18 months. This product redirects existing immune cells to eliminate unwanted cells in a patient waiting for a bone marrow transplant. This could replace chemotherapy. There is also a second product in preclinical development. Silver Falcon is issuing 228.6m shares at 3.5p each to acquire the company. It is also raising £2m at the same price. Readmission to standard list under the new name of Hemogenyx Pharmaceuticals (HEMO) will be on 5 October.

Papillon Holdings (PPHP) has agreed heads of terms to acquire Phestor and Greenway Activated Carbon, which are involved in ultra-supercapacitor development for energy storage and supply of active carbon produced from biomass. Greenway plans to set up bio-refineries to extract cellulose and other materials from sugar beet pulp, straw and brewery biomass. The active carbon produced can be used in the ultra-supercapacitors. Phestor was set up in October 2016, while Greenway was set up in March 2016, although its name was changed last month. James Etherington Thorpe, who is resident in Denmark, is the sole director of each of the companies. Papillon had previously ended talks with MyClubbetting.com (see below).

Ocelot Partners Ltd (OLOT) still had $413.9m in the bank at the end of June 2017 and it is still on the look out for companies involved with the European technology, media or telecoms sectors. Shares in Ocelot commenced trading on the standard list on 13 March, when the cash shell raised $418m at $10 a share (currently trading at $9.91 each). A further $7.35m was raised from founder preferred shares with one warrant attached to each share. There was a $34.1m non-cash charge relating to founder preferred share dividend rights in the figures to June 2017.

Standard list shell Rockpool Acquisitions (ROC) says that it has been approached by additional reverse takeover targets in a range of sectors. Rockpool wants to buy a Northern Ireland-based business.

Andrew Hore

Daily Actions – UK Main & AIM markets 19042016

IntellisysLogoDaily Actions is a daily summary analysis of changes in short term actions from our Daily Recs – AIM and Daily Recs Main markets reports. This report is typically distributed before the open of trading in London

AIM Market

ST Rec. changed
From To
Basic Resources    
Chaarat Gold Holdings Buy Neutral
MX Oil Neutral Buy
Clontarf Energy Neutral Buy
Red Rock Resources Neutral Buy
Rare Earth Minerals Buy Neutral
Chemicals    
Scapa Group Sell Neutral
Construction    
Elecosoft Neutral Buy
Financial Services    
Inland Homes Buy Neutral
Mirland Development Corporation Neutral Buy
Tiziana Life Sciences Neutral Buy
Health Care    
Premaitha Health Neutral Buy
Sareum Holdings Neutral Buy
Industrial Good & Services    
Billing Services Group Buy Neutral
Hargreaves Services Neutral Buy
Pipehawk Neutral Buy
Media    
Mirada Neutral Buy
Next Fifteen Communications Sell Neutral
Oil & Gas – Explorers    
Borders & Southern Petroleum Neutral Buy
Technology    
Cyan Holdings Neutral Buy
Toumaz Neutral Buy
Travel & Leisure    
Goals Soccer Centres Buy Neutral

Main Market

ST Rec. changed
From To
Building Materials & Fittings    
Titon Holdings Sell Neutral
Heavy Construction    
Galliford Try Neutral Buy
House Construction    
Bovis Homes Group Buy Neutral
Food & Drugs Stores    
Tesco Neutral Sell
Food Producers & Processors    
Devro Neutral Buy
Speciality & Other Finance    
Intermediate Capital Group Sell Neutral
Support Services    
VP Sell Neutral

 

RISK WARNING

Intellisys Intelligent Analysis Limited (‘Intellisys’) does not make personal recommendations. The information in this publication is provided solely to enable you to make your own investment decisions. If you are unsure about dealing in shares and other equity investments, you must contact your financial adviser as these types of investments may not be suitable for everyone. The value of stocks and shares, and the income from them, can fall as well as rise and you may not get back the full amount you originally invested. If denominated in a foreign currency, fluctuations in the exchange rate will also affect the value of stocks and shares and the income from them. Past performance is not necessarily a guide to future performance. You agree to abide fully with Intellisys’ Term & Conditions, which are available to www.intellisys.uk.com

 

The full reports are available from Intellisys Intelligent Analysis website (www.intellisys.uk.com) by clicking on the ‘Research’ tab.

 

DISCLAIMER: Intellisys Intelligent Analysis Limited has prepared this report. Intellisys (“Intellisys”) is the trading name of Intellisys Intelligent Analysis Limited. Intellisys Intelligent Analysis Limited is a provider of financial research reports that indicate the possible value of quoted company shares. The information contained within any and all of Intellisys’ reports are designed to present an objective assessment of the possible value or relative value of a company and/or an actuarial sector or stock market index. Intellisys utilises as extensive as possible range of valuation tools and proprietary systems to derive its outputs. The base data for the models are derived from sources believed to be accurate but Intellisys Intelligent Analysis Limited does not warrant or guarantee the accuracy or reliability of the source data or its models and proprietary systems. Subscribers, and casual readers, should not rely upon the Intellisys’ research outputs when forming specific investment decisions but should seek advice specific to their situation and investment requirements from a person authorised under the Financial Services and Markets Act 2000, before entering into any investment agreement.

Intellisys Intelligent Analysis Limited has used reasonable care and skill in compiling the content of this report. No representation or warranty, expressed or implied, is given by any person as to the accuracy or completeness or accuracy of the information and no responsibility or liability is accepted to the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. In no event will Intellisys Intelligent Analysis Limited, Intellisys or any of its officers, employees or agents be liable to any other party for any direct, indirect, special or other consequential damages arising from the use of this report.

The Intellisys Intelligent Analysis Limited and/or Intellisys reports are not directed to any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the publication or availability of the Intellisys Intelligent Analysis Limited and/or Intellisys information may be prohibited. Persons in respect of whom such prohibitions apply must not access the Intellisys Intelligent Analysis Limited and/or Intellisys reports. Neither this document, nor any copy in whatever form of media, may be taken or transmitted into the United States, Canada, Australia, Ireland, South Africa or Japan or into any jurisdiction where it would be unlawful to do so. Any failure to comply with this restriction may constitute a violation of relevant local securities laws. Recipients of Intellisys Intelligent Analysis Limited and/or Intellisys reports outside the UK are not covered by the rules and regulations made for the protection of investors in the UK.

Any user distributing information taken from any Intellisys Intelligent Analysis Limited or Intellisys report and/or the Intellisys website, in whatever form, to any other person, agrees to attach a copy of this Disclaimer and the Terms and Conditions of Use pages and obtain the agreement of such other person to comply with the terms set forth.

Intellisys’ published reports are published for information purposes and only available to market counterparties, high net-worth and sophisticated individual investors.

No Intellisys report constitutes an offer or invitation to trade, sell, purchase or acquire any shares or other financial instruments in any company or any interest therein, nor shall it form the basis of any contract entered into for the sale of shares or any other financial instrument in any company.

Intellisys Intelligent Analysis Limited believes that the information within each and any of its reports to be correct, but its accuracy or completeness cannot be guaranteed. No representation or warranty, expressed or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or mis-statements, negligent or otherwise.

Intellisys Intelligent Analysis Limited (including its Directors, employees and representatives) or a connected person may have positions in or options or other financial instruments on any of the securities mentioned within a report, and may buy, sell or offer to purchase or sell such securities from time to time, subject to restrictions imposed by internal rules.

Subscribers, and casual reader, are reminded that the value of any financial instrument may go up or down and that past performance is not necessarily a guide to future performance.

Intellisys Intelligent Analysis Limited is not registered with or regulated by any financial regulatory authority and does not offer, provide or purport to provide or offer investment advice. Intellisys Intelligent Analysis Limited can be contacted at Woodfield Cottage, The Street, Mortimer, Berkshire, United Kingdom RG7 3DW.

 

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.